AMYLIN PHARMACEUTICALS INC - FORM 10-Q - EX-32.1 - CERTIFICATIONS PURSUANT TO U.S.C. SECTION 1350 - May 5, 2011

Attached files

file filename
10-Q - FORM 10-Q - AMYLIN PHARMACEUTICALS INCd10q.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER - AMYLIN PHARMACEUTICALS INCdex311.htm
EX-10.1 - NON-EMPLOYEE DIRECTORS' EQUITY INCENTIVE PLAN - AMYLIN PHARMACEUTICALS INCdex101.htm
EX-10.2 - FORM OF NON-EMPLOYEE DIRECTORS' EQUITY INCENTIVE PLAN - AMYLIN PHARMACEUTICALS INCdex102.htm
EX-10.3 - FORM OF 2009 EQUITY INCENTIVE PLAN - AMYLIN PHARMACEUTICALS INCdex103.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER - AMYLIN PHARMACEUTICALS INCdex312.htm
EX-10.4 - AMENDMENT TO EXENATIDE MANUFACTURING AGREEMENT - AMYLIN PHARMACEUTICALS INCdex104.htm
EXCEL - IDEA: XBRL DOCUMENT - AMYLIN PHARMACEUTICALS INCFinancial_Report.xls

Exhibit 32.1

CERTIFICATION

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350, as adopted), Daniel M. Bradbury, the President and Chief Executive Officer of Amylin Pharmaceuticals, Inc. (the “Company”), and Mark G. Foletta, the Senior Vice President, Finance and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:

 

1. The Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2011, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and

 

2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by the Periodic Report and results of operations of the Company for the period covered by the Periodic Report.

Dated: May 5, 2011

 

/S/    DANIEL M. BRADBURY       /S/     MARK G. FOLETTA

Daniel M. Bradbury

     Mark G. Foletta

President and Chief Executive Officer

     Senior Vice President, Finance and Chief Financial Officer

AMYLIN PHARMACEUTICALS INC Reports

Also read